NDANASALSPRAYPriority Review
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPRAVATO (esketamine hydrochloride) is a nasal spray small-molecule medication approved by the FDA on March 5, 2019, developed by Johnson & Johnson. It is indicated for treatment of critical illness, sepsis, and surgical injury. The product operates as an NMDA receptor antagonist, offering a rapid-onset mechanism distinct from traditional therapies. SPRAVATO represents a novel therapeutic approach in acute care settings where rapid intervention is clinically critical.
$0.1BPart D
13.8 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Reward Emotion Learning and Ketamine Study
Started Aug 2021
70 enrolled
DepressionMajor Depressive DisorderTreatment Resistant Depression
Why This Matters for Your Career
Worked on SPRAVATO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.